Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sarcoma
Phase 2: Non-Small-Cell Lung Cancer|Ovarian Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TCD11379 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2014-10-01 |
|
| OPSALIN | P2 |
Completed |
Ovarian Cancer |
2014-07-01 |
|
| TCD11270 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-10-01 |
|
| 2007-003592-39 | P3 |
Completed |
Sarcoma |
2013-04-17 |